Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

ClinicalTrials.gov ID: NCT00394563

Public ClinicalTrials.gov record NCT00394563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Parallel Arm, Placebo-Controlled, Double-Blind, Multiple-Dose Study of the Safety and Efficacy of RN624 in Adults With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.

Study identification

NCT ID
NCT00394563
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
450 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Last update posted
Oct 11, 2009

2006 – 2007

United States locations

U.S. sites
48
U.S. states
27
U.S. cities
45
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35209 —
Pfizer Investigational Site Phoenix Arizona 85013 —
Pfizer Investigational Site Phoenix Arizona 85023 —
Pfizer Investigational Site Tucson Arizona 85712 —
Pfizer Investigational Site Anaheim California 92801 —
Pfizer Investigational Site Cypress California 90630 —
Pfizer Investigational Site National City California 91950 —
Pfizer Investigational Site Sacremento California 95817 —
Pfizer Investigational Site Stamford Connecticut 06905 —
Pfizer Investigational Site Waterbury Connecticut 06708 —
Pfizer Investigational Site Daytona Beach Florida 32114 —
Pfizer Investigational Site North Miami Florida 33161 —
Pfizer Investigational Site Ocala Florida 34474 —
Pfizer Investigational Site Tampa Florida 33614-7118 —
Pfizer Investigational Site Atlanta Georgia 30328 —
Pfizer Investigational Site Honolulu Hawaii 96813 —
Pfizer Investigational Site Honolulu Hawaii 96814 —
Pfizer Investigational Site Boise Idaho 83704 —
Pfizer Investigational Site Evansville Indiana 47713 —
Pfizer Investigational Site Merrillville Indiana 46410 —
Pfizer Investigational Site Louisville Kentucky 40202 —
Pfizer Investigational Site Baltimore Maryland 21224-6821 —
Pfizer Investigational Site Wheaton Maryland 20902 —
Pfizer Investigational Site Worcester Massachusetts 01610 —
Pfizer Investigational Site Kansas City Missouri 64114 —
Pfizer Investigational Site St Louis Missouri 63141 —
Pfizer Investigational Site Omaha Nebraska 68114 —
Pfizer Investigational Site Las Vegas Nevada 89123 —
Pfizer Investigational Site Reno Nevada 89502 —
Pfizer Investigational Site Albuquerque New Mexico 87102 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site Charlotte North Carolina 28210-8503 —
Pfizer Investigational Site Charlotte North Carolina 28210 —
Pfizer Investigational Site Greensboro North Carolina 27401 —
Pfizer Investigational Site Raleigh North Carolina 27612 —
Pfizer Investigational Site Columbus Ohio 43212 —
Pfizer Investigational Site Zanesville Ohio 43701 —
Pfizer Investigational Site Portland Oregon 97239 —
Pfizer Investigational Site Bethlehem Pennsylvania 18015 —
Pfizer Investigational Site Duncansville Pennsylvania 16635 —
Pfizer Investigational Site Greer South Carolina 29651 —
Pfizer Investigational Site Jackson Tennessee 38305 —
Pfizer Investigational Site Knoxville Tennessee 37920 —
Pfizer Investigational Site Austin Texas 78705 —
Pfizer Investigational Site San Antonio Texas 78217 —
Pfizer Investigational Site Midvale Utah 84047 —
Pfizer Investigational Site Charlottesville Virginia 22911 —
Pfizer Investigational Site Yakima Washington 98902 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00394563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 11, 2009 · Synced Sep 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00394563 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →